Class Action Lawsuit Filed Against Corcept Therapeutics for Securities Law Violations
Class Action Lawsuit Against Corcept Therapeutics
On March 30, 2026, DJS Law Group announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT), emphasizing significant concerns regarding violations of securities laws. The lawsuit particularly focuses on alleged infractions of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 as enforced by the U.S. Securities and Exchange Commission.
Case Background
The class period for this lawsuit spans from October 31, 2024, to December 30, 2025, during which shareholders who bought shares are strongly encouraged to reach out to the law firm to explore potential lead plaintiff roles. Importantly, being appointed as a lead plaintiff is not a prerequisite for receiving any form of recovery.
As detailed in the complaint, Corcept is accused of issuing misleading statements to the market regarding the efficacy and approval status of its product candidate, relacorilant. Despite receiving warnings from the FDA on multiple occasions indicating that the clinical data supporting relacorilant was insufficient, the company allegedly misled investors by asserting that the product was
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.